The results indicated that AML derived miR-1246 is highly-expressed and directly-targeted the human leucine rich repeats and immunoglobulin like domains 1 (LRIG1), as a negatively regulator of receptor tyrosine kinase signaling, to activate the signal transducer and activator of transcription 3 (STAT3) pathway so that, by up-regulating LRIG1, miR-1246 inhibitor/EV-encapsulated miR-1246 inhibitor can suppress the viability and colony formation abilities but promote the apoptosis and differentiation of LSCs through inactivation of STAT3 pathway [116]. Here, LRIG1 is linked to acute myeloid leukemia.